DrugPatentWatch Database Preview
Details for Patent: 7,091,208
Which drugs does patent 7,091,208 protect, and when does it expire?
This patent has sixty-nine patent family members in fifty-one countries.
Summary for Patent: 7,091,208
Title: | Pyrrolo[2,3-D]pyrimidine compounds |
Abstract: | A compound of the formula ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases. |
Inventor(s): | Blumenkopf; Todd A. (Old Lyme, CT), Flanagan; Mark E. (Gales Ferry, CT), Munchhof; Michael J. (Salem, CT) |
Assignee: | Pfizer Inc. (New York, NY) |
Application Number: | 11/211,217 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 7,091,208
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer Inc | XELJANZ XR | tofacitinib citrate | TABLET, EXTENDED RELEASE;ORAL | 208246-001 | Feb 23, 2016 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | TREATMENT OF RHEUMATOID ARTHRITIS | ➤ Try a Free Trial | ||||
Pf Prism Cv | XELJANZ | tofacitinib citrate | TABLET;ORAL | 203214-001 | Nov 6, 2012 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | TREATMENT OF RHEUMATOID ARTHRITIS | ➤ Try a Free Trial | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 7,091,208
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
7,265,221 | Pyrrolo[2,3-d]pyrimidine compounds | ➤ Try a Free Trial |
7,601,727 | Pyrrolo[2,3-d]pyrimidine compounds | ➤ Try a Free Trial |
6,627,754 | Pyrrolo[2,3-d]pyrimidine compounds | ➤ Try a Free Trial |
RE41783 | Pyrrolo[2,3-D]pyrimidine compounds | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 7,091,208
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
African Regional IP Organization (ARIPO) | 1905 | ➤ Try a Free Trial | |||
Argentina | 026534 | ➤ Try a Free Trial | |||
Austria | 257157 | ➤ Try a Free Trial | |||
Austria | 380031 | ➤ Try a Free Trial | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |